Improving Survival in EGFR-Mutated NSCLC with Osimertinib

Created using ChatSlide

This presentation highlights the landmark findings from the ADAURA trial, focusing on overall survival improvements with Osimertinib in EGFR-mutant, resected non-small cell lung cancer (NSCLC). Published in NEJM on June 4, 2023, by Masahiro Tsuboi and colleagues, the study is a phase 3, double-blind, randomized clinical trial involving 682 patients at stages IB-IIIA. Key results demonstrate a significant 5-year survival improvement and a favorable safety profile. The discussion covers the...